Drug maker Octapharma USA has appointed David Holliday as VP commercial development, the company said.
Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.
Generic drug maker Hospira has enrolled the first patient in a late-stage clinical trial of a biosimilar drug for treating kidney disease.
Diplomat Specialty Pharmacy has received limited distribution rights for a neovascular age-related macular degeneration treatment.
Endo Pharmaceuticals announced a short-term supply constraint of analgesic products, including Opana ER, due to the temporary shutdown of a manufacturing facility operated by Novartis Consumer Health.
Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.
Sandoz has launched a shampoo used to treat severe scalp psoriasis, the generic drug maker said.
The Food and Drug Administration has granted fast-track designation to a drug currently under development by Achillion Pharmaceuticals for hepatitis C, the company said.
Biogen Idec and Isis Pharmaceuticals will work together on a drug invented by Isis for spinal muscular atrophy, the two companies said.
The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said Tuesday.